

**November 16, 2011 (London, UK)**  
*What Defines Success in Mediation?*

What defines success in mediation? Conventional wisdom might suggest that a mediation which does not result in a settlement on the day itself constitutes failure. But is this really the case? As the costs of litigation and arbitration continue to increase and mediation is increasingly used as one of a menu of options for resolving large scale and ever more complex disputes, the mediation itself may form only one step on the road toward settlement. In this seminar, a distinguished panel of in-house counsel will discuss their views on what, in the modern ADR world, defines success in mediation.

**Featured Panelists:**

- **Richard Blann, Head of Litigation, Lloyd's Banking Group- UK**
- **John Gilbert, Senior Legal Adviser, Dispute Resolution Team, BP- UK**
- **Erin Gleason Alvarez, Director, Office of Dispute Resolution and Litigation Management, Chartis Insurance- USA**
- **Ute Joas-Quinn, Associate General Counsel, Upstream International Functions, Shell- The Netherlands**
- **Anthony Monaghan, Manager, Enforcement and Financial Crime Division, Financial Services Authority- UK**
- **Alexander Oddy, Partner and Head of ADR, Herbert Smith- UK**

**Welcome Remarks:**

- **Olivier P. André, Special Counsel and Director of Dispute Resolution Services, CPR Institute- USA**
- **Dr. Gillian Dada, Member of CPR's European Executive Board, Head of Product Litigation Corporate (UK & Europe), GlaxoSmithKline- UK**

**Moderator:**

- **David Phillips, Professional Development Lawyer, Dispute Resolution, Herbert Smith- UK**

---

**October 19, 2011 (Boston, MA)**  
*Successful ADR Strategies For Life Sciences Companies: What Young Lawyers Should Know*

This event covered a wide range of issues concerning the use of ADR in the life sciences industry, including the pros/cons of using ADR to resolve disputes between collaboration/licensing/distribution partners, different ADR options available to life

sciences companies, and tips for drafting ADR clauses in contracts. Welcome remarks were made by CPR Board Member Robert H. Mnookin, Williston Professor of Law; Director, Harvard Negotiation Research Project; Chair, Program on Negotiation. The event was hosted by Mintz Levin Cohn Ferris Glovsky & Popeo, P.C.

**Panelists:**

- **Sarah Weil**, Senior Attorney, Commercial Litigation Department, Abbott Laboratories
- **Maria Castner**, Associate General Counsel-US, Qiagen
- **John Delehanty**, CPR Distinguished Neutral; Mintz Levin- New York
- **Joseph Vittiglio**, Vice President and Corporate Counsel, AVEO Pharmaceuticals
- **Christopher L. Gaenzle**, Assistant General Counsel - Litigation, Pfizer Inc.

**Moderator: Samuel Davenport**, Mintz Levin-Boston

---

**June 28, 2011 (Washington, DC)**

***Early Case Assessment: How Corporations Decide What Dispute Resolution Mechanism is Right for Them***

This well-attended seminar was moderated by Michael D. Nolan, Partner, of Milbank Tweed, Hadley & McCloy LLP and welcoming remarks were made by Hon. William H. Webster, Milbank, Tweed, Hadley & McCloy LLP and CPR's Chairman of the Board. There was a panel discussion, followed by a Q&A period.

**Panelists:**

- **Michael C. Bisignano**, Vice President, Legal & Deputy General Counsel, Blackboard Inc.
- **David H. Burt**, Corporate Counsel, E. I. du Pont de Nemours and Company
- **Stephen A. Chernow**, Associate General Counsel, Intelsat
- **Pamela Corrie**, General Counsel and Chief Risk Counsel, GE Capital
- **Brennan J. Torregrossa**, Assistant General Counsel, GlaxoSmithKline



*If you missed it, you can access this event online at West:*

**[Early Case Assessment: How Corporations Decide What Dispute Resolution Mechanism is Right for Them](#)**

---